ALISO VIEJO, Calif.—RxSight, Inc. (NASDAQ: RXST), an ophthalmic medical device company focused on improving vision after cataract surgery, has announced select preliminary financial results for the second quarter of 2026 and provided updates to its standalone product pipeline. This follows the announcement on July 6 about the company’s strategic collaboration with Alcon to develop and commercialize light-adjustable presbyopia-correcting intraocular lenses. Total company revenue for the second quarter of 2026 is expected to be approximately $32 million to $34 million, which includes $5 million to $7 million in revenue recognized from the RxSight Alcon strategic collaboration, with the specific amount expected to be reported in August with the company’s financial results for the second quarter of 2026.
Second-quarter sales are projected to reach approximately $27 million. This total includes the sale of 24,917 light adjustable lens (LAL) units and 11 light delivery devices (LDD) units, alongside 1 rental unit placement.
The company expects cash, cash equivalents and short-term investments of approximately $209 million as of June 30, 2026.
“While we faced meaningful commercial headwinds in Q2, including from more widespread competitive trialing, the unique ability of RxSight’s light adjustable technology to customize visual outcomes continued to deliver significant clinical benefits to thousands of patients around the world,” said Ron Kurtz, CEO and president of RxSight. “To position the company for deeper penetration of current, next-generation, and collaboration products, we are accelerating investments in our LAL sales force and commercial capabilities, while maintaining a disciplined approach to overall spending.”
He added, “By leveraging our differentiated technology, large customer base, strong balance sheet and exciting pipeline, we believe RxSight is well positioned to drive both high-margin implant sales and future royalty income, thereby empowering doctors to deliver the industry’s premier outcomes for even more of their patients.”
Additionally, the company adjusted its full-year 2026 revenue guidance to a range of $140 million to $160 million. This updated outlook includes both standalone RxSight sales and revenue recognized from the RxSight Alcon collaboration, with expected sales lowered to between $110 million and $120 million from the prior projection of $120 million to $135 million, the company said.
For Q2, the gross margin is projected to reach 73 percent to 75 percent, outperforming the prior guidance of 70 percent to 72 percent. Meanwhile, operating expenses are anticipated to be at the upper bound of the $150 million to $160 million range, aligning with previous estimates.
RxSight also announced that it is developing a new suite of adjustable IOLs built on its next-generation light adjustable lens technology platform, designed for improved workflow and enhanced performance. This suite includes the next-generation LAL, engineered for best-in-class visual quality, optical clarity, and post-operative refractive optimization to achieve targeted results.
Additionally, the next-generation LAL+ is designed to improve intermediate vision for daily tasks while preserving high-quality optical performance, the company noted, while the LAL toric provides built-in astigmatism correction with the ability for post-operative refinement of residual sphere and cylinder to maximize uncorrected visual acuity.
